Novo Nordisk (NVO) Trailing P/Es: LLY 38, NOV 10 Forward P/Es: LLY 26, NVO 11 Estimated 2026 sales growth: LLY 26%, NVO -8% Estimated 2025 EPS growth: LLY 43%, NVO -6% Cash per share: LLY $8.14, NVO $6.07 Institutional ownership: LLY 84.6%, NVO 9.5% In terms of value, NVO has LLY beat by a mile, trading at less than a third of LLY on a trailing price-to-earnings basis and just under half of it on a forward price-to-earnings basis
It's not an easy switch but there are some patients, perhaps those who could benefit from losing 6-8%, who have tried other means and might benefit
Water permeability and mechanical strength of polyunsaturated lipid bilayers
For a smaller group of patients, symptoms interfere with work, sleep, and social activities
DOI:10.1016/j
Instead of three large meals, try eating five or six very small snacks throughout the day